Merz North America has announced the nationwide availability of Naftin (naftifine HCl) Gel 2%, which was recently approved by the U.S. FDA for the treatment of interdigital-type tinea pedis.
The topical antifungal brand improves on the original formulation of Naftin (naftifine HCl) Gel 1% by delivering the efficacy of naftifine hydochloride with a once-daily application treatment regimen. In clinical studies, Naftin Gel 2% demonstrated continuous improvement in post-treatment efficacy rates for up to four weeks after treatment regimen had ended. “We are pleased to be able to provide physicians and their patients with a new option for the safe and effective treatment of interdigital-type tinea pedis. Merz remains committed to advancing the quality of care in the medical dermatology space, and we believe the launch of Naftin (naftifine HCl) Gel 2% is evidence of our ongoing leadership in the topical antifungal category,“ said Greg Besase, vice president and head of U.S. dermatology for Merz North America. Naftin (naftifine HCl) Gel 2% is an allylamine antifungal that treats interdigital-type tinea pedis by killing the Trichophyton rubrum fungus. In clinical trials, Naftin (naftifine HCl) Gel 2% exhibited fungicidal activity against a broad spectrum of dermatophytes, as well as clinically significant anti-bacterial and anti-inflammatory effects.
The approval of Naftin (naftifine HCl) Gel 2% is based on results from two pivotal U.S. clinical trials involving 47 investigational sites and included 1715 adult patients. The results indicate that patients treated with Naftin Gel 2% experienced clinically significant cure rates when compared to placebo. The most likely adverse reactions are application skin reactions (2%).